|
Mode of Action (MoA)
|
None
|
|
Evidence
|
AcrIE2 was functionally validated using a phage knockout strategy. Wild-type phage DMS3m carrying the acrIE2 gene (gene 30) infected strain SMC4386 efficiently, while a mutant version lacking acrIE2 (replaced by a type I-F anti-CRISPR) was unable to form plaques due to CRISPR interference (ECO_0001038). Complementary assays using JBD8 plaque formation in plasmid-expressing strains further demonstrated ACR3-30's ability to inhibit the type I-E system in vivo. Expression of ACR3-30 had no effect on E. coli’s type I-E system or on type I-F systems
|
|
MoA Category
|
unknown
|
|
Subtype(s) of the defence system(s) inhibited by the protein
Defence Subtype
|
Pseudomonas aeruginosa SMC4386 type I-E CRISPR-Cas
|
|
Relevant publication(s)
DOI
|
10.1128/mBio.00896-14
|
|
Other components of the anti-defence system
Multicomponent System
|
-
|
|
Known structure in PDB
PDB ID
|
-
|
|
Genome(s) encoding the protein
Protein Source
|
Pseudomonas phage JBD88a
|
|
Defence system(s) inhibited by the protein
Defences
|
CRISPR-Cas
|